Oleclumab

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Freitag, April 5, 2024
CDTX, Colorectal cancer, Drug, Adenosine, Patient, SAN, Tavarua, AACR, Therapy, Cancer, Pathology, CCR5, CD73, DFC, San Diego Convention Center, Oleclumab, Escape Room, Vaccine

SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced the company will deliver four poster presentations, including one late-breaking poster presentation, at this year’s American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 at the San Diego Convention Center in San Diego, California. The presentations highlight data on the company’s multispecific CD73/PD-1 drug Fc-conjugate (DFC), its CCR5-targeting DFC, and CBO421, its lead oncology DFC candidate targeting CD73.

Key Points: 
  • The presentations highlight data on the company’s multispecific CD73/PD-1 drug Fc-conjugate (DFC), its CCR5-targeting DFC, and CBO421, its lead oncology DFC candidate targeting CD73.
  • “Our Cloudbreak platform has quickly produced DFC candidates effective in preclinical studies across various cancers with specific disease targets.
  • This week, we are sharing data on our CCR5 DFC program for the first time, which has demonstrated robust efficacy as a monotherapy in mouse models of colorectal cancer.
  • Targeting CCR5 has the potential to improve response rates to immune checkpoint inhibitor therapies, which could have a greater impact for patients unresponsive to these current treatment options.

Innate Pharma Reports First Quarter 2022 Financial Results and Business Update

Retrieved on: 
Dienstag, Mai 10, 2022
Biotechnology, Pharmaceutical, Health, Oleclumab, GEMOX, Cetuximab, Trastuzumab, PFS, B-ALL, American Association for Cancer Research, PTCL, Safety, Myelodysplastic syndrome, Investor, Tetra, Antibody, MF, Immune system, Company, ESMO, Patient, American Journal of Clinical Oncology, American Association, IPH, Oncology, Congress, Sanofi, Research, ORR, ATM, KIR3DL2, American depositary receipt, Novo Nordisk, Telephone, European Society for Medical Oncology, Association, Acute myeloid leukemia, Euronext Paris, NSCLC, AACR, Acute lymphoblastic leukemia, Cancer, Institute, Part, Mycosis fungoides, CRT, Tumor microenvironment, Webcast, Journal, Progression-free survival, PD-L1, IPHA, AstraZeneca, Bristol Myers Squibb, Oxaliplatin, Pharmaceutical industry, Fine chemical, Vaccine, Durvalumab, MD, Nasdaq, Intrinsic and extrinsic properties, Monalizumab

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today reported its consolidated financial results for the quarter ending March 31, 2022.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today reported its consolidated financial results for the quarter ending March 31, 2022.
  • This means our cash position is considerably strengthened to fund our pipeline ambitions into 2024, said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma.
  • In March 2022, Innate announced the opening of a new MF all-comers cohort in the TELLOMAK study.
  • Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca

Retrieved on: 
Freitag, April 29, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Cancer, NK, Antibody, Novo Nordisk, Safety, Immune system, Euronext Paris, Progression-free survival, PD-L1, PFS, Patient, Oncology, Journal, European Society for Medical Oncology, Lymphatic system, Neoplasm, NSCLC, Lung cancer, ESMO, IPH, ORR, American Journal of Clinical Oncology, Bristol Myers Squibb, Oleclumab, AstraZeneca, IPHA, CRT, Squamous cell carcinoma, Tumor microenvironment, Congress, IIIC, Survival, Sanofi, Pharmaceutical industry, Vaccine, Monalizumab, Durvalumab, Nasdaq, MD, Intrinsic and extrinsic properties

Dosing of the first patient in this trial has triggered a $50 million milestone payment from AstraZeneca to Innate.

Key Points: 
  • Dosing of the first patient in this trial has triggered a $50 million milestone payment from AstraZeneca to Innate.
  • We are very pleased that our key late-stage asset, monalizumab, has progressed into a second Phase 3 trial with our partner, AstraZeneca.
  • Detailed results from the randomized COAST Phase 2 trial were published in the Journal of Clinical Oncology on April 22, 2022.
  • Including the $50 million payment triggered by dosing the first patient in the Phase 3 PACIFIC-9 clinical trial, Innate Pharma has received $450 million to date.

Innate Pharma Third Quarter 2021 Report

Retrieved on: 
Dienstag, November 16, 2021
Biotechnology, Pharmaceutical, Health, Oncology, AML, Oxaliplatin, Progression-free survival, Cancer, European Society for Medical Oncology, Congress, CD16, ESMO, Tumor microenvironment, Bristol Myers Squibb, Webcast, Oncology, Cell, PFS, Institute, NCR1, Neck, Acute myeloid leukemia, Euronext Paris, Telephone, Â, CET, Cetuximab, Novo Nordisk, Patient, Natural killer T cell, Investor, Oleclumab, Society, GEMOX, IO, Metastasis, NSCLC, ORR, Immunotherapy, COAST, Head, AstraZeneca, SITC, Tetra, Immune system, CD123, NK, PTCL, IPHA, Society for Immunotherapy of Cancer, Neoplasm, Company, Antibody, ADCC, IPH, Fine chemical, Pharmaceutical industry, Vaccine

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced its revenues and cash position for the first nine months of 2021.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced its revenues and cash position for the first nine months of 2021.
  • ET)
    The live webcast will be available at the following link:
    Participants may also join via telephone using the following dial in numbers:
    This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com .
  • In September and November 2021, Innate also presented at the ESMO 2021 and SITC conferences respectively.
  • Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

ORIC Pharmaceuticals Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

Retrieved on: 
Dienstag, September 21, 2021
CD73, Food, Clinical trial, Neoplasm, Securities Act of 1933, ORIC, HER2, Oleclumab, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Security (finance), Therapy, Drug Quality and Security Act, U.S. Securities and Exchange Commission, FDA, LinkedIn, Environment, Prostate cancer, Twitter, Industry, CTA, Antibody, SAN, Risk, COVID-19, PRC2, IND, EGFR, Securities Exchange Act of 1934, Nasdaq, AMP, SEC, EED, GLOBE, Pharmaceutical industry, Vaccine

ORIC-533 was discovered internally at ORIC, is wholly owned, and is a highly potent, orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy and immunotherapy-based treatment regimens.

Key Points: 
  • ORIC-533 was discovered internally at ORIC, is wholly owned, and is a highly potent, orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy and immunotherapy-based treatment regimens.
  • ORIC-533 is a highly potent, orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy and immunotherapy-based treatment regimens.
  • ORIC-533 has demonstrated greater potency in preclinical studies compared to an antibody approach, other small molecule CD73 inhibitors and inhibitors of adenosine receptors.
  • ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients lives by Overcoming Resistance In Cancer.

Monalizumab Data from COAST Trial Presented at ESMO Congress 2021

Retrieved on: 
Freitag, September 17, 2021
Squamous cell carcinoma, Cancer, Bristol Myers Squibb, European Society for Medical Oncology, Oleclumab, Immune system, Novo Nordisk, Antibody, Durvalumab, Cell biology, Sanofi, Patient, ESMO, IPHA, Natural killer T cell, Oncology, Safety, ORR, IIIC, CRT, IPH, Progression-free survival, Neoplasm, Tumor microenvironment, NSCLC, Lymphatic system, Lung cancer, GLOBE, Intrinsic and extrinsic properties, AstraZeneca, Euronext Paris, PFS, Congress, Vaccine, Pharmaceutical industry

MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on September 17, 2021.

Key Points: 
  • MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on September 17, 2021.
  • To read more about the Phase 2 COAST results, please see AstraZenecas press release here .
  • Were pleased to see the monalizumab COAST results, particularly the improved clinical outcomes for patients with unresectable, Stage III non-small cell lung cancer, said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma.
  • The ongoing development for monalizumab is focused on investigating monalizumab in various combination strategies in different malignancies.

IMFINZI Combined With Novel Immunotherapies Improved Clinical Outcomes for Patients With Unresectable, Stage III Non-Small Cell Lung Cancer

Retrieved on: 
Freitag, September 17, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Monalizumab, CT, Incidence, Prednisone, European Society for Medical Oncology, Oleclumab, Safety, Warning, Carboplatin, Breathe Me, Doctor of Philosophy, Patient, Infection, ESMO, Company, Ballistic missile, Risk, HIV disease progression rates, Neoplasm, Phase, AEGEAN, ORR, CRT, HR, Solution, MD, Death, Progression-free survival, NSCLC, Hope, Etoposide, Cisplatin, Creatinine, Lung cancer, Pneumonitis, Radiation, Administration, AstraZeneca, PFS, Yale Cancer Center, Oncology, Congress, Pharmaceutical industry, Medical imaging, Medical device, Vaccine, Stage III NSCLC, COAST, PACIFIC-R, IMFINZI® (durvalumab), Oleclumab, Monalizumab, AstraZeneca Support Programs, AstraZeneca in lung cancer, AstraZeneca in immunotherapy, AstraZeneca in oncology, AstraZeneca, STAGE III NSCLC, COAST, PACIFIC-R, IMFINZI® (DURVALUMAB), OLECLUMAB, MONALIZUMAB, ASTRAZENECA SUPPORT PROGRAMS, ASTRAZENECA IN LUNG CANCER, ASTRAZENECA IN IMMUNOTHERAPY, ASTRAZENECA IN ONCOLOGY, ASTRAZENECA

The Company is also testing novel combinations with IMFINZI in the Phase II NeoCOAST trial in the neoadjuvant early-stage setting.

Key Points: 
  • The Company is also testing novel combinations with IMFINZI in the Phase II NeoCOAST trial in the neoadjuvant early-stage setting.
  • IMFINZI is indicated for the treatment of adult patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
  • Sequential vs Concurrent Chemoradiation for Stage III NonSmall Cell Lung Cancer: Randomized Phase III Trial RTOG 9410.
  • Current Standards and Clinical Trials in Systemic Therapy for Stage III Lung Cancer: What is New?

Monalizumab and ANKET™ Data Will Be Presented at ESMO 2021 Virtual Congress

Retrieved on: 
Donnerstag, September 2, 2021
Cancer, PFS, Sanofi, Progression-free survival, Congress, NCR1, Technology, IPH, Durvalumab, Cell biology, Immune system, GLOBE, Oleclumab, CD16, Therapy, Tumor microenvironment, Antibody, ESMO, ORR, Lymphatic system, Natural killer T cell, Immunotherapy, NK, Tetra, Intrinsic and extrinsic properties, Safety, DVM, Patient, Euronext Paris, Novo Nordisk, NSCLC, Bristol Myers Squibb, Neoplasm, AstraZeneca, IPHA, Vaccine, Pharmaceutical industry

MARSEILLE, France, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that two oral presentations will be highlighted at the ESMO 2021 Virtual Congress.

Key Points: 
  • MARSEILLE, France, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that two oral presentations will be highlighted at the ESMO 2021 Virtual Congress.
  • In addition, Innate will present pre-clinical data from its next-generation, proprietary, multi-specific NK cell engager platform known as ANKETTM (Antibody-based NK cell Engager Therapeutics).
  • Monalizumab is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells.
  • The ongoing development for monalizumab is focused on investigating monalizumab in various combination strategies in different malignancies.